Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019)
NCT ID: NCT04379310
Last Updated: 2020-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
54 participants
OBSERVATIONAL
2020-05-01
2020-05-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia
NCT04599998
Steroid and Anticoagulant Therapy in covid19
NCT05021588
The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
NCT04263402
Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults
NCT03400735
Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut University Hospital
NCT04481360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For the study, investigators will recruit patients diagnosed with COVID-19 pneumonia between March 11th, 2020 (the date at which the first case of Covid-19 in Turkey officially declared) and April 15th, 2020 in emergency, internal medicine and cardiology outpatient clinics, retrospectively. All of the demographic features, complaints on admission, reports of computed tomography (CT) scans of the chest without intravenous contrast issued by the staff radiologist, c-reactive protein (CRP) and complete blood count (CBC) values on admission will be recorded retrospectively. Their polymerase chain reaction (PCR) test results will be derived from the hospital records based on public health covid-19 database notifications and list of medications taken regularly for more than 8 weeks before the diagnosis of COVID-19 pneumonia from the national pharmacy database. Information about other systemic diseases and major medical conditions of patients will be procured from the medical histories gained by relevant physicians. Patient taking each drug group will be compared to those not taking that drugs in terms of clinical and demographical features mentioned above. Statistical analysis will be performed by using SPSS software.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
covid-19 pneumonia
diagnosed with covid-19 by using PCR and computed tomography scans
ACE Inhibitors and Calcium Channel Blockers
effect of drugs on patients with covid-19 pneumonia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACE Inhibitors and Calcium Channel Blockers
effect of drugs on patients with covid-19 pneumonia
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* not newly diagnosed.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Nisantasi University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Murat Civan
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hasan Haciosman
Role: STUDY_CHAIR
academic staff, MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vital Hospital
Bahçelievler, Istanbul, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20200504441
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.